

*Sub D1*

1. (Amended) An [adjuvant which] immunogenic composition comprising an adjuvant and an antigen; wherein said adjuvant and said antigen are joined together; and wherein said adjuvant is adapted to stimulate a B-lymphocyte cell surface receptor, CD40.

*B1*

2. (Amended) A vaccine including the [adjuvant] immunogenic composition according to Claim 1. *Sub D1*

3. (Amended) A vaccine according to Claim 2 wherein [said vaccine comprises] said antigen is a T-cell dependent [and/] or T-cell independent antigen, or part [(s) thereof] of said T-cell dependent or T-cell independent antigen.

*B2*

5. (Amended) A vaccine according to Claim 2 wherein said adjuvant is an antibody raised against said CD40 [receptor], or a part of said antibody that is effective at binding CD40 [thereof].

*B3*

12. (Amended) A vaccine according to Claim [11] 3 wherein said antigen is a protein or part thereof, and [it] said antigen is fused to said adjuvant so as to provide a fusion protein.

*Sub D2*

13. (Amended) A vaccine according to Claim 2 further comprising at least one cytokine.

*B4*

15. (Amended) A method for the manufacture of a [novel] vaccine capable of enhancing immunity [which method comprises the selection] comprising

(a) selecting [of] a suitable T-cell dependent and/or T-cell independent antigen, or parts thereof, and [association or combination of]

(b) associating or combining said antigen with an adjuvant; wherein said adjuvant is adapted to stimulate B-lymphocyte receptor, CD40.

17. (Amended) A [system] kit for the manufacture of a vaccine capable of enhancing T-cell independent or T-cell dependent immunity [which system comprises] comprising a cell expressing a selected T-cell dependent and/or T-cell independent antigen, or parts thereof, and [also] an adjuvant capable [or] of stimulating a B-lymphocyte receptor, CD40.

18. (Amended) A [system] kit according to Claim 17 wherein said vaccine is capable of enhancing T-cell independent immunity.

19. (Amended) A [system] kit according to Claim 17 wherein one or both of said antigen and adjuvant is provided with a secretion signal whereby expression of one or both of said antigen or adjuvant results in secretion of one or both of said antigen or adjuvant from said cell.

*b5*  
20. (Amended) A [system] kit according to Claim 17 wherein the expression of said antigen and adjuvant is adapted such that a single fusion protein [is] can be manufactured by said cell.

21. (Amended) A [system] kit according to Claim 20 wherein said single fusion protein is adapted for secretion from said cell.

22. (Amended) A nucleic acid molecule encoding [an adjuvant] the fusion protein according to Claim [1] 12.

REMARKS

Reconsideration of this Application is respectfully requested. Applicants have canceled Claims 11 and 14 without prejudice. Claims 1-3, 5, 12, 13, 15, and 17-22 have been amended to more particularly point out and distinctly claim the subject matter of the invention. Applicants have added the properties of Claim 11 to amended Claim 1, whereas the Examiner has asserted